RxDoctor Payments Data

Jeffrey Johnson, DO

Internal Medicine · Decatur, ALNPI 1992723274

Payments from drug & device makers

$4,831in general payments, 2019–2025

Across 317 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$738
  • Amgen$652
  • Bayer$490
  • Novartis$249
  • Amarin Pharma, Inc.$245
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,819100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,831 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$134,279
Medicare patients
253
Services billed
2,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$132,990
EliquisApixaban133$102,743
Repatha SureclickEvolocumab96$65,331
MounjaroTirzepatide50$50,907
JardianceEmpagliflozin74$48,769
XareltoRivaroxaban39$37,499
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$34,976
SynjardyEmpagliflozin/Metformin Hcl22$29,036
TrulicityDulaglutide19$26,780
JanumetSitagliptin Phos/Metformin Hcl47$26,138
KerendiaFinerenone17$19,312
EntrestoSacubitril/Valsartan16$14,601
Synjardy XrEmpagliflozin/Metformin Hcl18$14,419
MyrbetriqMirabegron26$11,378
Tresiba Flextouch U-100Insulin Degludec17$10,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,001$132,99096 claims
PfizerEliquis$132$102,743133 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$139$92,224114 claims
Lilly USA, LLCMounjaro, Trulicity$738$77,68769 claims
GSKTrelegy Ellipta$211$34,97637 claims
MerckJanumet$115$26,13847 claims
BayerKerendia$490$19,31217 claims
NovartisEntresto$249$14,60116 claims
AbbVieSynthroid$98$5,95172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →